

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Masahiro IWAMOTO et al.

Application No.: 08/878,177

Filed: June 18, 1997

For: CELL CALCIFICATION
SUPPRESSING PROTEINS, AND
GENES OF THE PROTEINS



Group Art Unit: 1633

Examiner: M. Wilson

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the restriction requirement mailed October 26, 1998, Applicants provide the following response.


In a written restriction requirement, the Examiner required restriction under 35 U.S.C. § 121 and categorized the claimed subject matter as follows: Group I (claims 1 and 5) drawn to protein; Group II (claim 2) drawn to DNA; Group III (claims 3-4, 15, 17, and 19) drawn to pharmaceutical compositions comprising a protein; Group IV (claims 6-7) drawn to antibodies; Group V (claims 8-9 and 12) drawn to a method of measuring gene expression using a probe against DNA; Group VI (claims 8 and 10-13) drawn to a method of measuring gene expression

using an antibody; Group VII (claim 14) drawn to a method of screening compounds using transformed cells; and, Group VIII (claims 16 and 18) drawn to a pharmaceutical composition comprising DNA. Applicants hereby provisionally elect to prosecute Group II (claim 2).

If there are any other fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By: 
John G. Smith
Reg. No. 33,818

Dated: January 8, 1999

MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036
202-467-7000

JGS/DAB/slm